Cost Analysis of Ertapenem Therapy for Urinary Tract Infections and Assessment of Its Suitability for Outpatient Parenteral Antibiotic Therapy Programme in Turkey
Journal Title: Mediterranean Journal of Infection, Microbes and Antimicrobials - Year 2017, Vol 6, Issue 1
Abstract
Introduction: The primary aim of this study was to evaluate whether there was a difference between outpatient parenteral antibiotic therapy (OPAT) and inpatient parenteral antibiotic therapy (IPAT) costs of ertapenem for urinary tract infections (UTI’s) due to extended-spectrum beta-lactamase (ESBL)-producing Gram-negative bacilli, and to discuss suitability of ertapenem for OPAT programme of Turkey for the near future. Materials and Methods: A total of 53 patients hospitalized with the diagnosis of UTI and treated with ertapenem were retrospectively evaluated. The cost of ertapenem treatment as IPAT was actual costs retrieved from the hospital records. The estimated cost of the same antibiotic for the same patients as an OPAT programme was then calculated and the costs were compared. Results: The cost difference between IPAT and OPAT was ₺ 12.305 (€ 5783). Outpatient parenteral antibiotic therapy programme would provide an estimated 20% reduction in treatment costs. The estimated number of bed days saved, if the patients had received the treatment as OPAT, was calculated to be 583 days, which constitutes about 5% of the total number of hospitalization days. Conclusion: Applying ertapenem therapy through OPAT programme for UTIs caused by ESBL-producing Gram-negative bacilli will decrease the financial burden of health expenditures and the number of inpatient bed days in Turkey.
Authors and Affiliations
Bahar ÖRMEN, Nesrin TÜRKER, Nurbanu SEZAK, Zerrin KARA, Figen KAPTAN, Tuna DEMİRDAL, Melih Kaan SÖZMEN
Keywords
Related Articles
- EP ID EP689352
- DOI 10.4274/mjima.2017.7
- Views 141
- Downloads 0
Herpes Simplex Virus Encephalitis: An Update
Herpes simplex virus (HSV) is the most frequent cause of sporadic infective encephalitis in adults. Despite antiviral therapies, the case fatality rate is moderate to high (5 to 30% according studies and countries). Tool...
Chronic Hepatitis C Treatment with New Antiviral Agents
Recent advances in our knowledge of hepatitis C virus (HCV) molecular biology have enabled improvements in the efficacy and tolerability of HCV treatment, and in this regard many direct-acting antiviral (DAA) agents have...
Distribution of AdeABC Efflux System Genes in Acinetobacter baumannii Isolated from Blood Cultures of Hospitalized Patients and Their Relationship with Carbapenem and Aminoglycoside Resistance
Introduction: The increasing emergence of multidrug-resistant (MDR) Acinetobacter infections has become a significant challenge for physicians and clinical microbiologists owing to the difficulties arising during therapy...
Acute Cervical Myelitis as a Rare Complication of Pneumococcal Meningitis in Adults
No Abstract
Evaluation of Infections in Hospitalised Pregnant Women
Introduction: Hormonal and immunological changes in pregnancy may lead to an increase in infectious diseases caused by some pathogens. In this study, we aimed to determine the types of infections and treatment approaches...